CL2016002402A1 - Composiciones inmunológicas que contiene histophilus somni atenuado - Google Patents

Composiciones inmunológicas que contiene histophilus somni atenuado

Info

Publication number
CL2016002402A1
CL2016002402A1 CL2016002402A CL2016002402A CL2016002402A1 CL 2016002402 A1 CL2016002402 A1 CL 2016002402A1 CL 2016002402 A CL2016002402 A CL 2016002402A CL 2016002402 A CL2016002402 A CL 2016002402A CL 2016002402 A1 CL2016002402 A1 CL 2016002402A1
Authority
CL
Chile
Prior art keywords
attenuated
histophilus somni
compositions containing
strain
immunological compositions
Prior art date
Application number
CL2016002402A
Other languages
English (en)
Inventor
Tammy Kolander
Paularaj Lawrence
Russell Bey
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CL2016002402A1 publication Critical patent/CL2016002402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cepa atenuada de histophilus somni que en su secuencia genómica carece de ciertos genes que codifican factores de virulencia y que la hacen incapaz de causar infección en bovinos; composición inmunológica que la comprende; uso para provocar inmunidad protectora contra una cepa virulenta; composición de vacuna; cepa de desafío altamente virulenta; y método para aumentar virulencia en histophilus somni.
CL2016002402A 2014-03-25 2016-09-23 Composiciones inmunológicas que contiene histophilus somni atenuado CL2016002402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461970195P 2014-03-25 2014-03-25

Publications (1)

Publication Number Publication Date
CL2016002402A1 true CL2016002402A1 (es) 2017-05-26

Family

ID=52829377

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002402A CL2016002402A1 (es) 2014-03-25 2016-09-23 Composiciones inmunológicas que contiene histophilus somni atenuado

Country Status (19)

Country Link
US (2) US9592283B2 (es)
EP (2) EP3122374B1 (es)
JP (1) JP6405390B2 (es)
KR (1) KR101924271B1 (es)
CN (1) CN107197626B (es)
AU (1) AU2015236052B2 (es)
BR (1) BR112016021918A2 (es)
CA (1) CA2943786C (es)
CL (1) CL2016002402A1 (es)
DK (1) DK3488862T3 (es)
EA (1) EA038530B1 (es)
ES (1) ES2927971T3 (es)
HU (1) HUE059284T2 (es)
MX (1) MX373361B (es)
NZ (1) NZ724908A (es)
PH (1) PH12016501879B1 (es)
PL (1) PL3488862T3 (es)
TR (1) TR201907352T4 (es)
WO (1) WO2015148687A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927971T3 (es) * 2014-03-25 2022-11-14 Boehringer Ingelheim Animal Health Usa Inc Composiciones inmunológicas que contienen Histophilus Somni atenuado
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP7535896B2 (ja) * 2020-09-10 2024-08-19 株式会社Fuji 検出装置、作業機および検出方法
RU2754005C1 (ru) * 2020-10-29 2021-08-25 Федеральное государственное бюджетное научное учреждение "Федеральный научный центр - Всероссийский научно-исследовательский институт экспериментальной ветеринарии имени К.И. Скрябина и Я.Р. Коваленко Российской академии наук" (ФГБНУ ФНЦ ВИЭВ РАН) Штамм бактерий histophilus somni, предназначенный для получения моно- и поливалентных иммуногенных композиций, направленных на специфическую профилактику гистофилеза (стадного бесплодия) рогатого скота
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN113174374B (zh) * 2021-05-19 2022-07-22 西南民族大学 一种牛病毒性腹泻病毒弱毒株及其用途
CN118956701B (zh) * 2024-10-16 2025-02-11 金宇保灵生物药品有限公司 一种昏睡嗜血杆菌菌株及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6770273B1 (en) * 1998-09-25 2004-08-03 Regents Of The University Of California Vaccine based on attenuated Haemophilus somnus
AU6160599A (en) * 1998-09-25 2000-04-17 Regents Of The University Of California, The Vaccine based on attenuated (haemophilus somnus)
US20090068223A1 (en) * 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
EP2320943B1 (en) * 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
US9597386B2 (en) * 2012-04-05 2017-03-21 Boehringer Ingelheim Vetmedica, Inc. Outer membrane proteins of Histophilus somni and methods thereof
EP3062816B1 (en) * 2013-11-01 2020-08-05 Boehringer Ingelheim Animal Health USA Inc. Attenuated pasteurella multocida vaccines & methods of making & use thereof
ES2927971T3 (es) * 2014-03-25 2022-11-14 Boehringer Ingelheim Animal Health Usa Inc Composiciones inmunológicas que contienen Histophilus Somni atenuado

Also Published As

Publication number Publication date
MX373361B (es) 2020-05-25
AU2015236052A1 (en) 2016-11-10
US10098941B2 (en) 2018-10-16
HUE059284T2 (hu) 2022-11-28
AU2015236052B2 (en) 2018-05-10
CA2943786C (en) 2023-12-12
PH12016501879A1 (en) 2017-01-09
EA201691915A1 (ru) 2017-04-28
EP3122374A2 (en) 2017-02-01
ES2927971T3 (es) 2022-11-14
KR20160128427A (ko) 2016-11-07
CA2943786A1 (en) 2015-10-01
BR112016021918A2 (pt) 2017-10-24
WO2015148687A2 (en) 2015-10-01
MX2016012372A (es) 2017-05-30
CN107197626B (zh) 2021-03-02
EP3122374B1 (en) 2019-02-20
EP3488862B1 (en) 2022-05-04
WO2015148687A3 (en) 2015-12-23
NZ724908A (en) 2017-12-22
US20150273045A1 (en) 2015-10-01
US9592283B2 (en) 2017-03-14
CN107197626A (zh) 2017-09-22
JP2017517245A (ja) 2017-06-29
EP3488862A1 (en) 2019-05-29
DK3488862T3 (da) 2022-08-01
PL3488862T3 (pl) 2022-08-29
KR101924271B1 (ko) 2019-02-22
TR201907352T4 (tr) 2019-06-21
EA038530B1 (ru) 2021-09-10
JP6405390B2 (ja) 2018-10-17
PH12016501879B1 (en) 2017-01-09
US20170157232A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
MX378854B (es) Composiciones que comprenden cepas bacterianas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
PE20170243A1 (es) Composiciones de vacuna con adyuvante dual, preparacion y usos
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX2017016401A (es) Composiciones inmunogenas.
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
MX2017008055A (es) Vacunacion.
MX373395B (es) Vacuna de haemophilus parasuis para serovar tipo cuatro.
MX2019007973A (es) Composiciones universales de vacuna de la influenza.
ES2721755T3 (es) Vacunas contra el virus de la tilapia del lago
GB2515222A (en) Use of flagellin as a vaccine
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
BR112017004356A2 (pt) antígenos de streptococcus agalactiae associados a cepas virulentais em peixes
MX388527B (es) Composiciones adyuvantes y metodos relacionados.
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso